Sidetrade: Double-Digit Growth in Profitability in H1 2026

Sidetrade reported H1 2026 revenue of €34.8M, up 19% reported and 21% at constant currency, while EBIT rose 22% to €5.7M and net income increased 15% to €4.7M. New ARR bookings surged 112% to €5.16M—already 20% above full-year 2025—while TCV jumped 194% to €18.71M. AI-native products generated €1.02M of Q2 ARR, or 33% of new ARR, supporting management's unchanged target for AI-native products to exceed 50% of revenue by 2030. Organic subscription growth was only 6% excluding ezyCollect, but the strong 2026 booking rebound is expected to contribute increasingly from Q4 2026 and through 2027.

Analysis

ALBFR’s investable inflection is not the reported revenue growth but the booking mix: longer initial terms and a higher new-logo contribution create a deferred revenue conversion cycle that should become visible from Q4 2026 and accelerate through 2027. The key valuation question is whether investors underwrite the current organic subscription run-rate or capitalize the much stronger contracted pipeline; a sustained acceleration in reported organic growth would support both earnings revisions and a SaaS multiple re-rating. North American bookings materially exceeding its current revenue mix increases upside but also makes sales execution, implementation capacity, and dollar exposure the principal 2027 sensitivities.

Margin optics require scrutiny. Consolidated gross margin dilution from ezyCollect and EBIT’s dependence on a French R&D tax credit mean the headline operating-leverage narrative is less clean than the company’s like-for-like presentation suggests. The acquisition debt is inexpensive, but leverage becomes more consequential if booked AI products require greater GPU refresh, customer onboarding spend, or working capital than management implies; monitor cash conversion rather than adjusted EBIT.

The AI positioning may be differentiated in a regulated finance workflow, but commercial proof remains preliminary until beta deployments convert into production usage and expansion revenue. The company’s fixed-cost private compute model is a near-term advantage if utilization rises; conversely, it can become an underappreciated margin drag if AI-agent adoption stalls. NVDA has no actionable earnings sensitivity at Sidetrade’s scale, while HCKT’s recognition is reputational rather than a material revenue read-through.

Consensus is likely to reward the AI narrative immediately, but the more durable catalyst is evidence that usage-priced agent products lift net retention without cannibalizing legacy subscription pricing. The strongest falsifier is Q3/Q4 evidence that new ARR fails to translate into organic subscription growth, accompanied by renewed gross-margin compression or higher implementation costs.

Key Decisions for Investors

• Initiate a small, liquidity-adjusted long in ALBFR.PA only after confirming trading liquidity and Q3 revenue on October 20, 2026; add if organic subscription growth inflects above the prior 6% run-rate and management confirms Q4 pipeline conversion. Target a 6-12 month re-rating driven by 2027 revenue visibility; exit if organic growth remains sub-10% or consolidated EBIT margin declines despite the revenue ramp.
• Use a staged entry rather than chasing a press-release reaction: buy 50% ahead of Q3 only if the stock remains near pre-results levels, reserve 50% for post-release confirmation. The risk/reward depends on booked ARR converting to recognized revenue; without disclosure of retention, implementation timing, and customer concentration, treat this as a high-volatility Euronext Growth position rather than a core holding.
• Do not establish a directional NVDA position from this development. Sidetrade’s GPU purchases are immaterial to NVIDIA; use any claimed enterprise-sovereign-AI demand signal only as qualitative support within a broader NVDA thesis.
• Set alerts for AI beta production conversion in Q4 2026, 2027 organic subscription guidance, gross margin versus the 74% consolidated level, and operating cash flow after tax-credit timing. Evidence of rising agent consumption and stable gross margin would justify increasing ALBFR exposure; a slower rollout or elevated infrastructure spend would invalidate the operating-leverage case.